<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Statistical analysis | Dr. Xiaotao Shen</title>
    <link>https://www.shenxt.info/tags/statistical-analysis/</link>
      <atom:link href="https://www.shenxt.info/tags/statistical-analysis/index.xml" rel="self" type="application/rss+xml" />
    <description>Statistical analysis</description>
    <generator>Source Themes Academic (https://sourcethemes.com/academic/)</generator><language>en-us</language><copyright>©Xiaotao Shen 2023</copyright><lastBuildDate>Thu, 19 Jan 2023 00:00:00 +0000</lastBuildDate>
    <item>
      <title>Multi-omics microsampling for the profiling of lifestyle-associated changes in health</title>
      <link>https://www.shenxt.info/publication/journal-article/2023-nbme-microsampling/</link>
      <pubDate>Thu, 19 Jan 2023 00:00:00 +0000</pubDate>
      <guid>https://www.shenxt.info/publication/journal-article/2023-nbme-microsampling/</guid>
      <description>&lt;p&gt;Current healthcare practices are reactive and use limited physiological and clinical information, often collected months or years apart. Moreover, the discovery and profiling of blood biomarkers in clinical and research settings are constrained by geographical barriers, the cost and inconvenience of in-clinic venepuncture, low sampling frequency and the low depth of molecular measurements. Here we describe a strategy for the frequent capture and analysis of thousands of metabolites, lipids, cytokines and proteins in 10 μl of blood alongside physiological information from wearable sensors. We show the advantages of such frequent and dense multi-omics microsampling in two applications, the assessment of the reactions to a complex mixture of dietary interventions, to discover individualized inflammatory and metabolic responses; and deep individualized profiling, to reveal large-scale molecular fluctuations as well as thousands of molecular relationships associated with intra-day physiological variations (in heart rate, for example) and with the levels of clinical biomarkers (specifically, glucose and cortisol) and of physical activity.&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>massDatabase utilities for the operation of the public compound and pathway database</title>
      <link>https://www.shenxt.info/publication/journal-article/2022-bioinformatics-massdatabase/</link>
      <pubDate>Sat, 27 Aug 2022 00:00:00 +0000</pubDate>
      <guid>https://www.shenxt.info/publication/journal-article/2022-bioinformatics-massdatabase/</guid>
      <description>&lt;p&gt;One of the major challenges in liquid chromatography coupled to mass spectrometry data is converting many metabolic feature entries to biological function information, such as metabolite annotation and pathway enrichment, which are based on the compound and pathway databases. Multiple online databases have been developed. However, no tool has been developed for operating all these databases for biological analysis. Therefore, we developed massDatabase, an R package that operates the online public databases and combines with other tools for streamlined compound annotation and pathway enrichment. massDatabase is a flexible, simple and powerful tool that can be installed on all platforms, allowing the users to leverage all the online public databases for biological function mining. A detailed tutorial and a case study are provided in the Supplementary Material.&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Precision environmental health monitoring by longitudinal exposome and multi-omics profiling</title>
      <link>https://www.shenxt.info/publication/journal-article/2022-gr-exposome/</link>
      <pubDate>Tue, 02 Aug 2022 00:00:00 +0000</pubDate>
      <guid>https://www.shenxt.info/publication/journal-article/2022-gr-exposome/</guid>
      <description></description>
    </item>
    
    <item>
      <title>TidyMass an object-oriented reproducible analysis framework for LC–MS data profiling</title>
      <link>https://www.shenxt.info/publication/journal-article/2022-nc-tidymass/</link>
      <pubDate>Tue, 02 Aug 2022 00:00:00 +0000</pubDate>
      <guid>https://www.shenxt.info/publication/journal-article/2022-nc-tidymass/</guid>
      <description>&lt;p&gt;Reproducibility, traceability, and transparency have been long-standing issues for metabolomics data analysis. Multiple tools have been developed, but limitations still exist. Here, we present the tidyMass project (&lt;a href=&#34;https://www.tidymass.org/)&#34;&gt;https://www.tidymass.org/)&lt;/a&gt;, a comprehensive R-based computational framework that can achieve the traceable, shareable, and reproducible workflow needs of data processing and analysis for LC-MS-based untargeted metabolomics. TidyMass is an ecosystem of R packages that share an underlying design philosophy, grammar, and data structure, which provides a comprehensive, reproducible, and object-oriented computational framework. The modular architecture makes tidyMass a highly flexible and extensible tool, which other users can improve and integrate with other tools to customize their own pipeline.&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>metID an R package for automatable compound annotation for LC2MS-based data</title>
      <link>https://www.shenxt.info/publication/journal-article/2021-bioinformatics-metid/</link>
      <pubDate>Sat, 31 Jul 2021 00:00:00 +0000</pubDate>
      <guid>https://www.shenxt.info/publication/journal-article/2021-bioinformatics-metid/</guid>
      <description>&lt;p&gt;Accurate and efficient compound annotation is a long-standing challenge for LC–MS-based data (e.g.
untargeted metabolomics and exposomics). Substantial efforts have been devoted to overcoming this obstacle,
whereas current tools are limited by the sources of spectral information used (in-house and public databases) and
are not automated and streamlined. Therefore, we developed metID, an R package that combines information from
all major databases for comprehensive and streamlined compound annotation. metID is a flexible, simple and
powerful tool that can be installed on all platforms, allowing the compound annotation process to be fully automatic
and reproducible. A detailed tutorial and a case study are provided in Supplementary Materials.&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Metabolic Dynamics and Prediction of Gestational Age and Time to Delivery in Pregnant Women</title>
      <link>https://www.shenxt.info/publication/journal-article/2020-cell-pregnancy/</link>
      <pubDate>Thu, 25 Jun 2020 00:00:00 +0000</pubDate>
      <guid>https://www.shenxt.info/publication/journal-article/2020-cell-pregnancy/</guid>
      <description></description>
    </item>
    
    <item>
      <title>R语言常见统计预测模型</title>
      <link>https://www.shenxt.info/post/r-ml-model/</link>
      <pubDate>Wed, 16 Oct 2019 00:00:00 +0000</pubDate>
      <guid>https://www.shenxt.info/post/r-ml-model/</guid>
      <description>
&lt;script src=&#34;index_files/header-attrs/header-attrs.js&#34;&gt;&lt;/script&gt;

&lt;div id=&#34;TOC&#34;&gt;
&lt;ul&gt;
&lt;li&gt;&lt;a href=&#34;#lasso模型&#34;&gt;&lt;span class=&#34;toc-section-number&#34;&gt;0.0.1&lt;/span&gt; lasso模型&lt;/a&gt;&lt;/li&gt;
&lt;li&gt;&lt;a href=&#34;#references&#34;&gt;&lt;span class=&#34;toc-section-number&#34;&gt;0.0.2&lt;/span&gt; References&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;
&lt;/div&gt;

&lt;div id=&#34;lasso模型&#34; class=&#34;section level3&#34; number=&#34;0.0.1&#34;&gt;
&lt;h3&gt;&lt;span class=&#34;header-section-number&#34;&gt;0.0.1&lt;/span&gt; lasso模型&lt;/h3&gt;
&lt;p&gt;LASSO回归的特点是在拟合广义线性模型的同时进行变量筛选(variable selection)和复杂度调整(regularization).因此,不论因变量(dependent/response varaible)是连续的(continuous),还是二元或者多元离散的（discrete）,都可以用LASSO回归建模然后预测.这里的变量筛选是指不把所有的变量都放入模型中进行拟合,而是有选择的把变量放入模型从而得到更好的性能参数. 复杂度调整是指通过一系列参数控制模型的复杂度,从而避免过拟合(overfitting). 对于线性模型来说,复杂度与模型的变量数有直接关系,变量数越多,模型复杂度就越高. 更多的变量在拟合时往往可以给出一个看似更好的模型,但是同时也面临过度拟合的危险.此时如果用全新的数据去验证模型(validation),通常效果很差. 一般来说,变量数大于数据点数量很多,或者某一个离散变量有太多独特值时,都有可能过度拟合.&lt;/p&gt;
&lt;p&gt;LASSO回归的复杂度主要由参数&lt;span class=&#34;math inline&#34;&gt;\(\lambda\)&lt;/span&gt;(lambda)来控制.lambda越大,对变量较多的线性模型的惩罚力度就越大.最终获得一个变量较少的模型.&lt;/p&gt;
&lt;p&gt;另外还有一个参数&lt;span class=&#34;math inline&#34;&gt;\(\alpha\)&lt;/span&gt;(alpha)用来控制高度相关性模型的性状.LASSO回归时,alpha设置为1.&lt;/p&gt;
&lt;p&gt;使用&lt;code&gt;glmnet&lt;/code&gt;包可以进行LASSO回归.它可以对一系列不同的lambda值进行拟合,每次拟合都用到上一个lambda拟合的结果,从而大大提高了运行效率.&lt;/p&gt;
&lt;div id=&#34;常用参数如下&#34; class=&#34;section level4&#34; number=&#34;0.0.1.1&#34;&gt;
&lt;h4&gt;&lt;span class=&#34;header-section-number&#34;&gt;0.0.1.1&lt;/span&gt; 常用参数如下:&lt;/h4&gt;
&lt;ul&gt;
&lt;li&gt;&lt;code&gt;x&lt;/code&gt;: 自变量数据集,需要为matrix格式,行为观测列为变量.&lt;br /&gt;
&lt;/li&gt;
&lt;li&gt;&lt;code&gt;y&lt;/code&gt;: 因变量数据集,需要为matrix格式,只有一列.&lt;/li&gt;
&lt;li&gt;&lt;code&gt;family&lt;/code&gt;: 应变量类型.如果时连续性变量(也就是要做回归分析),&lt;code&gt;family&lt;/code&gt;应该为&lt;code&gt;gussian&lt;/code&gt;(高斯分布/正态分布)或者&lt;code&gt;poisson&lt;/code&gt;(泊松分布).如果为两分类不连续变量(factor类型,且只有两个levels),应设置为&lt;code&gt;binomial&lt;/code&gt;.如果时多分类不连续变量(factor类型,且多个levels),则应设置为&lt;code&gt;multinomial&lt;/code&gt;.如果设置为&lt;code&gt;cox&lt;/code&gt;,则y应当为一个两列的matrix,列名分别为&lt;code&gt;time&lt;/code&gt;和&lt;code&gt;status&lt;/code&gt;,&lt;code&gt;tiem&lt;/code&gt;为存活时间,&lt;code&gt;status&lt;/code&gt;为结局状态(1代表死亡,0代表还未死亡).&lt;/li&gt;
&lt;li&gt;&lt;code&gt;alpha&lt;/code&gt;: 在LASSO回归中,将其设置为1.&lt;/li&gt;
&lt;li&gt;&lt;code&gt;nlambda&lt;/code&gt;: 选取多少个lambda进行优化,默认为100.也就是使用100个lambda值拟合出100个系数不同的模型.&lt;/li&gt;
&lt;li&gt;&lt;code&gt;lambda&lt;/code&gt;: 提供lambda值,如果设置该值(一个或者多个),则会覆盖掉自动选择的lambda值.&lt;/li&gt;
&lt;li&gt;&lt;code&gt;standardize&lt;/code&gt;: 是否对数据进行标准化(scale),默认为TRUE.推荐自己对数据进行标准化,如果自己做过sca了,这里需要设置为FALSE.&lt;/li&gt;
&lt;/ul&gt;
&lt;/div&gt;
&lt;div id=&#34;构建模型&#34; class=&#34;section level4&#34; number=&#34;0.0.1.2&#34;&gt;
&lt;h4&gt;&lt;span class=&#34;header-section-number&#34;&gt;0.0.1.2&lt;/span&gt; 构建模型&lt;/h4&gt;
&lt;p&gt;构建模型之后,可以将其打印出来观察具体信息.&lt;/p&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;div id=&#34;references&#34; class=&#34;section level3&#34; number=&#34;0.0.2&#34;&gt;
&lt;h3&gt;&lt;span class=&#34;header-section-number&#34;&gt;0.0.2&lt;/span&gt; References&lt;/h3&gt;
&lt;ul&gt;
&lt;li&gt;&lt;a href=&#34;https://cosx.org/2016/10/data-mining-1-lasso/&#34; class=&#34;uri&#34;&gt;https://cosx.org/2016/10/data-mining-1-lasso/&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;
&lt;/div&gt;
</description>
    </item>
    
    <item>
      <title>Development of a Correlative Strategy To Discover Colorectal Tumor Tissue Derived Metabolite Biomarkers in Plasma Using Untargeted Metabolomics</title>
      <link>https://www.shenxt.info/publication/journal-article/2018-ac-zhuozhong/</link>
      <pubDate>Sun, 23 Dec 2018 00:00:00 +0000</pubDate>
      <guid>https://www.shenxt.info/publication/journal-article/2018-ac-zhuozhong/</guid>
      <description>&lt;p&gt;The metabolic profiling of biofluids using untargeted metabolomics provides a promising choice to discover metabolite biomarkers for clinical cancer diagnosis. However, metabolite biomarkers discovered in biofluids may not necessarily reflect the pathological status of tumor tissue, which makes these biomarkers difficult to reproduce. In this study, we developed a new analysis strategy by integrating the univariate and multivariate correlation analysis approach to discover tumor tissue derived (TTD) metabolites in plasma samples. Specifically, untargeted metabolomics was first used to profile a set of paired tissue and plasma samples from 34 colorectal cancer (CRC) patients. Next, univariate correlation analysis was used to select correlative metabolite pairs between tissue and plasma, and a random forest regression model was utilized to define 243 TTD metabolites in plasma samples. The TTD metabolites in CRC plasma were demonstrated to accurately reflect the pathological status of tumor tissue and have great potential for metabolite biomarker discovery. Accordingly, we conducted a clinical study using a set of 146 plasma samples from CRC patients and gender-matched polyp controls to discover metabolite biomarkers from TTD metabolites. As a result, eight metabolites were selected as potential biomarkers for CRC diagnosis with high sensitivity and specificity. For CRC patients after surgery, the survival risk score defined by metabolite biomarkers also performed well in predicting overall survival time (p = 0.022) and progression-free survival time (p = 0.002). In conclusion, we developed a new analysis strategy which effectively discovers tumor tissue related metabolite biomarkers in plasma for cancer diagnosis and prognosis.&lt;/p&gt;
</description>
    </item>
    
  </channel>
</rss>
